Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2016

01.04.2016 | Research Article

Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan

verfasst von: Yuichi Tasaka, Daiki Yasunaga, Mamoru Tanaka, Akihiro Tanaka, Takashige Asakawa, Ikuo Horio, Yoshiro Miyauchi, Hiroaki Araki

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background Pharmaceutical interventions by community and hospital pharmacists can improve medication safety and result in financial savings. Their effect has not been fully explored in Japan. Objective To evaluate the economic and safety contributions of various pharmaceutical interventions by community and hospital pharmacists in Japan. Setting Two hospitals and eight community pharmacies in Ehime Prefecture, Japan, in 2014–2015. Method Pharmacists entered data about pharmaceutical interventions via the internet, and the data were divided into 11 types of interventions. The economic impact was estimated based on the rate of avoidance of serious adverse drug reactions and the monetary cost of these reactions in the Japanese compensation system. The cost saving from adjusting prescriptions to take account of unused prescription drugs was calculated using drug prices from the national health insurance scheme. Main outcome measure The number of pharmaceutical interventions and their economic impact. Results The total cost savings from 500 to 509 pharmaceutical interventions by community and hospital pharmacists were US$207,126.6 and US$592,840, respectively. Community pharmacists mainly intervened to correct prescription errors. They also adjusted 135 prescriptions to take account of unused prescription drugs. This potentially improved patients’ adherence and contributed to effective use of medication. Pharmaceutical interventions by hospital pharmacists facilitated avoidance of 10 serious adverse drug reactions, and included 42 transvenous antimicrobial therapy interventions, 88 interventions in cancer chemotherapy, and 47 monitoring recommendations. Hospital pharmacists helped improve patients’ quality of life using more aggressive interventions besides correcting prescription errors. Over half of pharmaceutical interventions by community and hospital pharmacists contributed to avoidance of adverse drug reactions. Conclusion These results suggest the importance of pharmaceutical interventions by both community and hospital pharmacists in reducing increasing medical expenses and contributing to safety and effectiveness of medication. They also suggest that community and hospital pharmacists have different roles.
Literatur
1.
Zurück zum Zitat Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.CrossRefPubMed Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.CrossRefPubMed
2.
Zurück zum Zitat Miguel A, Azevedo LSF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21:1139–54.CrossRefPubMed Miguel A, Azevedo LSF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21:1139–54.CrossRefPubMed
3.
Zurück zum Zitat Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:601–8.CrossRefPubMed Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:601–8.CrossRefPubMed
4.
Zurück zum Zitat Perrone V, Conti V, Venegoni M, Scotto S, Degli Esposti L, Sangiorgi D, et al. Seriousness, preventability, and burden impact of reported adverse drug reactions in Lombardy emergency departments: a retrospective 2-year characterization. CEOR. 2014;6:505–14. Perrone V, Conti V, Venegoni M, Scotto S, Degli Esposti L, Sangiorgi D, et al. Seriousness, preventability, and burden impact of reported adverse drug reactions in Lombardy emergency departments: a retrospective 2-year characterization. CEOR. 2014;6:505–14.
5.
Zurück zum Zitat Zed PJ, Haughn C, Black KJ, Fitzpatrick EA, Ackroyd-Stolarz S, Murphy NG, et al. Medication-related emergency department visits and hospital admissions in pediatric patients: a qualitative systematic review. J Pediatr. 2013;163:477–83.CrossRefPubMed Zed PJ, Haughn C, Black KJ, Fitzpatrick EA, Ackroyd-Stolarz S, Murphy NG, et al. Medication-related emergency department visits and hospital admissions in pediatric patients: a qualitative systematic review. J Pediatr. 2013;163:477–83.CrossRefPubMed
6.
Zurück zum Zitat Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35:769–81.CrossRefPubMedPubMedCentral Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35:769–81.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155:1949–56.CrossRefPubMed Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155:1949–56.CrossRefPubMed
8.
Zurück zum Zitat Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41:191–9. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41:191–9.
9.
Zurück zum Zitat Gertler SA, Coralic Z, López A, Stein JC, Sarkar U. Root cause analysis of ambulatory adverse drug events that present to the emergency department. J Patient Saf 2014; Epub ahead of print. Gertler SA, Coralic Z, López A, Stein JC, Sarkar U. Root cause analysis of ambulatory adverse drug events that present to the emergency department. J Patient Saf 2014; Epub ahead of print.
10.
Zurück zum Zitat Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRefPubMedPubMedCentral Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tasaka Y, Tanaka A, Ido K, Tanaka M, Araki H. Estimation of the economic impact associated with pharmaceutical interventions. Jpn J Pharm Health Care Sci. 2014;40:208–14.CrossRef Tasaka Y, Tanaka A, Ido K, Tanaka M, Araki H. Estimation of the economic impact associated with pharmaceutical interventions. Jpn J Pharm Health Care Sci. 2014;40:208–14.CrossRef
12.
Zurück zum Zitat Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73:1484–90.CrossRefPubMed Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73:1484–90.CrossRefPubMed
14.
Zurück zum Zitat Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285:2114–20.CrossRefPubMed Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285:2114–20.CrossRefPubMed
18.
Zurück zum Zitat Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ, et al. Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust. 2003;179:135–9.PubMed Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ, et al. Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust. 2003;179:135–9.PubMed
19.
Zurück zum Zitat Janus ED, Bunker SJ, Kilkkinen A, Mc Namara K, Philpot B, Tideman P, et al. Prevalence, detection and drug treatment of hypertension in a rural Australian population: the Greater Green Triangle Risk Factor Study 2004–2006. Intern Med J. 2008;38:879–86.CrossRefPubMed Janus ED, Bunker SJ, Kilkkinen A, Mc Namara K, Philpot B, Tideman P, et al. Prevalence, detection and drug treatment of hypertension in a rural Australian population: the Greater Green Triangle Risk Factor Study 2004–2006. Intern Med J. 2008;38:879–86.CrossRefPubMed
20.
Zurück zum Zitat Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19:1190–6.CrossRefPubMed Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19:1190–6.CrossRefPubMed
21.
Zurück zum Zitat Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.CrossRefPubMedPubMedCentral Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31–7.PubMedPubMedCentral Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31–7.PubMedPubMedCentral
23.
Zurück zum Zitat Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol. 2004;11:e267–73.PubMed Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol. 2004;11:e267–73.PubMed
24.
Zurück zum Zitat McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–6.CrossRefPubMed McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–6.CrossRefPubMed
Metadaten
Titel
Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan
verfasst von
Yuichi Tasaka
Daiki Yasunaga
Mamoru Tanaka
Akihiro Tanaka
Takashige Asakawa
Ikuo Horio
Yoshiro Miyauchi
Hiroaki Araki
Publikationsdatum
01.04.2016
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2016
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0245-6

Weitere Artikel der Ausgabe 2/2016

International Journal of Clinical Pharmacy 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.